Defence Therapeutics Inc. (F:DTC) — Market Cap & Net Worth
Market Cap & Net Worth: Defence Therapeutics Inc. (DTC)
Defence Therapeutics Inc. (F:DTC) has a market capitalization of $17.21 Million (€14.72 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #25596 globally and #2210 in its home market, demonstrating a -4.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Defence Therapeutics Inc.'s stock price €0.29 by its total outstanding shares 57369970 (57.37 Million). Review DTC current and long-term liabilities to assess the company's total debt and financial obligations.
Defence Therapeutics Inc. Market Cap History: 2021 to 2026
Defence Therapeutics Inc.'s market capitalization history from 2021 to 2026. Data shows change from $252.19 Million to $19.25 Million (-31.23% CAGR).
Defence Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Defence Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DTC by Market Capitalization
Companies near Defence Therapeutics Inc. in the global market cap rankings as of June 19, 2026.
Key companies related to Defence Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Defence Therapeutics Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, Defence Therapeutics Inc.'s market cap moved from $252.19 Million to $ 19.25 Million, with a yearly change of -31.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €19.25 Million | -31.67% |
| 2025 | €28.17 Million | -3.23% |
| 2024 | €29.11 Million | -72.18% |
| 2023 | €104.63 Million | -14.05% |
| 2022 | €121.73 Million | -51.73% |
| 2021 | €252.19 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Defence Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.21 Million USD |
| MoneyControl | $17.21 Million USD |
| MarketWatch | $17.21 Million USD |
| marketcap.company | $17.21 Million USD |
| Reuters | $17.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more